Natural history, and impact of surgery and radiation on survival outcomes of men diagnosed with low-grade prostate cancer at ≤ 55 years of age: a 25-year follow-up of > 60,000 men.
Long-term survival
Prostate cancer
Radical prostatectomy
Radiotherapy
Young men
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
30
09
2021
accepted:
10
09
2022
pubmed:
29
9
2022
medline:
25
1
2023
entrez:
28
9
2022
Statut:
ppublish
Résumé
Low-grade prostate cancer has low mortality rates at 10 years; however, it is unclear if the response is sustained for up to 25 years of follow-up. Using Surveillance, Epidemiology, and End Results database, the overall and cancer-specific mortality rates were compared among men ≤ 55 years of age diagnosed with low-grade prostate cancer that either had radical prostatectomy, radiotherapy, or no known treatment. Of the 62,772 men diagnosed with low-grade prostate cancer between 1975 and 2016, about 60%, 20% and 20% of men underwent radical prostatectomy, radiotherapy, and no known treatment, respectively. At a median follow-up of 10 years, almost 2% and 7% of men died of prostate cancer and other causes, respectively. The overall mortality was significantly better in radical prostatectomy group compared to no known treatment group (HR 1.99, CI 1.84-2.15, P value < 0.001), but not between the radiotherapy and no known treatment groups. Moreover, the overall and cancer-specific mortality rates in the radiotherapy group were almost two and three times compared to the radical prostatectomy group, respectively (HR 2.15, CI 2.01-2.29, P value < 0.001 for overall mortality and HR 2.87, CI 2.5-3.29, P value < 0.001 for cancer-specific mortality). The study confirms low mortality rates in men diagnosed with low-grade prostate cancer for over 25 years' follow-up. While radical prostatectomy improves survival significantly compared to no known treatment, radiotherapy is associated with an increase in overall and cancer-specific mortality, which may be related to long-term toxicities.
Identifiants
pubmed: 36171482
doi: 10.1007/s11255-022-03363-6
pii: 10.1007/s11255-022-03363-6
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
295-300Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359-386
doi: 10.1002/ijc.29210
Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7–33
doi: 10.3322/caac.21654
Bleyer A, Spreafico F, Barr R (2020) Prostate cancer in young men: an emerging young adult and older adolescent challenge. Cancer 126(1):46–57
doi: 10.1002/cncr.32498
SEER Cancer Stat Facts: Prostate Cancer. National Cancer Institute. Bethesda. https://seer.cancer.gov/statfacts/html/prost.html .
Tosoian JJ, Mamawala M, Epstein JI et al (2020) Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort. Eur Urol 77(6):675–682
doi: 10.1016/j.eururo.2019.12.017
List of SEER Registries
Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA (2010) Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 102(20):1584–1598
doi: 10.1093/jnci/djq366
Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL (2001) Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst 93(23):1822–1823
doi: 10.1093/jnci/93.23.1822
SEER Cause-specific Death Classification
Grossman DC, Curry SJ, Owens DK et al (2018) Screening for prostate cancer: us preventive services task force recommendation statement. JAMA 319(18):1901–1913
doi: 10.1001/jama.2018.3710
Schröder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328
doi: 10.1056/NEJMoa0810084
Andriole GL, Crawford ED, Grubb RL 3rd et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310–1319
doi: 10.1056/NEJMoa0810696
Albertsen PC (2005) Is screening for prostate cancer with prostate specific antigen an appropriate public health measure? Acta Oncol 44(3):255–264
doi: 10.1080/02841860410002815
Carter HB, Partin AW, Walsh PC et al (2012) Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol 30(35):4294–4296
doi: 10.1200/JCO.2012.44.0586
Bryant RJ, Oxley J, Young GJ et al (2020) The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. BJU Int 125(4):506–514
doi: 10.1111/bju.14987
Hamdy FC, Donovan JL, Lane JA et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424
doi: 10.1056/NEJMoa1606220
Bill-Axelson A, Holmberg L, Ruutu M et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18):1708–1717
doi: 10.1056/NEJMoa1011967
Wilt TJ, Jones KM, Barry MJ et al (2017) Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med 377(2):132–142
doi: 10.1056/NEJMoa1615869
Klotz L, Vesprini D, Sethukavalan P et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33(3):272–277
doi: 10.1200/JCO.2014.55.1192
Haffner MC, Mosbruger T, Esopi DM et al (2013) Tracking the clonal origin of lethal prostate cancer. J Clin Invest 123(11):4918–4922
doi: 10.1172/JCI70354
Lange EM, Salinas CA, Zuhlke KA et al (2012) Early onset prostate cancer has a significant genetic component. Prostate 72(2):147–156
doi: 10.1002/pros.21414
Ohri N, Dicker AP, Showalter TN (2012) Late toxicity rates following definitive radiotherapy for prostate cancer. Can J Urol 19(4):6373–6380
Wallis CJ, Mahar AL, Choo R et al (2016) Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ 352:i851
doi: 10.1136/bmj.i851
Mohammed N, Kestin L, Ghilezan M et al (2012) Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys 82(1):204–212
doi: 10.1016/j.ijrobp.2010.10.009
SEER Training module - Morphology and Grade. https://training.seer.cancer.gov/prostate/abstract-code-stage/morphology.html . Accessed 25 Sept 2020